Atyr PHARMA (ATYR) to Release Quarterly Earnings on Thursday

Atyr PHARMA (NASDAQ:ATYR) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect Atyr PHARMA to post earnings of ($0.19) per share for the quarter.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. On average, analysts expect Atyr PHARMA to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Atyr PHARMA Trading Up 1.4 %

NASDAQ ATYR opened at $3.52 on Thursday. The firm’s fifty day moving average price is $3.37 and its 200 day moving average price is $3.33. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66. The company has a market capitalization of $312.78 million, a price-to-earnings ratio of -3.74 and a beta of 0.95.

Analyst Ratings Changes

Several brokerages have issued reports on ATYR. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Cantor Fitzgerald started coverage on Atyr PHARMA in a research report on Monday, January 6th. They issued an “overweight” rating for the company. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a research report on Friday, March 14th. Finally, Leerink Partners began coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $18.60.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.